BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

April 30, 2027

Conditions
Advanced or Metastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
BIOLOGICAL

BC001+Sintilimab+XELOX

patients will be given : BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously once every three weeks; Sintilimab 3mg/kg(body weight\<60kg)or 200mg(body weight≥60kg)intravenously once every three weeks; Oxaliplatin 130mg/m2 intravenously once every three weeks; Capecitabine 1000mg/m2 orally once daily in the first two weeks of each three-week treatment cycle.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

INDUSTRY